U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Shanghai Desano Chemical Pharmaceutical Co., Ltd. - 06/14/2017
  1. Warning Letters

CLOSEOUT LETTER

Shanghai Desano Chemical Pharmaceutical Co., Ltd.

Recipient:
Shanghai Desano Chemical Pharmaceutical Co., Ltd.

United States

Issuing Office:

United States

 

  

Black HHS-Blue FDA Logo

 

 

 
10903 New Hampshire Avenue
Silver Spring, MD 20993 

June 14, 2017

Jinliang Li, Ph.D
Chairman of the Board
Shanghai Desano Chemical Pharmaceutical Co., Ltd.
1479 Zhangheng Road
Zhangjiang High-Tech Park
Shanghai 201203, China

Reference: Warning Letter 320-16-18

Location: Shanghai Desano Chemical Pharmaceutical Co., Ltd.
              No. 417 Binhai Road, Laogang Town,
              Pudong District, Shanghai 201302, China

Dear Dr. Li:

The Food and Drug Administration has completed an evaluation of Shanghai Desano Chemical Pharmaceutical Co., Ltd. (FEI 3006895951) corrective actions in response to Warning Letter 320-16-18, dated June 06, 2016. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

If you have any questions regarding this letter, you may contact me at the above address or number: (301) 796-5339.

For more information on the U.S. FDA, please visit our website at www.fda.gov.

Sincerely,
/S/

Cesar E. Matto
Compliance Officer
Division of Drug Quality I

Back to Top